Skip to main content
. 2022 Jan 25;12:766066. doi: 10.3389/fonc.2022.766066

Figure 2.

Figure 2

Progression free survival (A) and overall survival (B) of patients treated with TKIs + LCRT or TKIs alone for oligometastatic NSCLC harboring EGFR activating mutations.